Analyst consensus implies roughly 144% upside from current levels and the stock holds above its 200-day moving average, but the business scores below the minimum quality threshold — burning cash with negative free cash flow and no competitive moat — while 23% of the float is sold short and the put-to-call ratio stands at 55, reflecting deep institutional skepticism about near-term outcomes.
Thesis pillars
- Analyst Consensus Upside→Stable
- Below Floor Business Quality→Stable
- Extreme Short And Options Skepticism→Stable
- +1 more pillar — see the Why tab for full reasoning
Corvus Pharmaceuticals, Inc. (CRVS) Stock Analysis
Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $15.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 6.09; Below-average business quality.
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company whose lead candidate, soquelitinib, an oral ITK inhibitor, is in a registrational Phase 3 trial for relapsed peripheral T cell lymphoma and a Phase 2 trial for atopic dermatitis. The company has not generated... Read more
Sell if holding. Engine safety override at $15.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 6.09; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.3/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news events none recent, earnings proximity 34d clear, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Corvus Pharmaceuticals, Inc.
About Corvus Pharmaceuticals, Inc.
Corvus Pharmaceuticals' lead candidate soquelitinib, an oral ITK inhibitor, is in a registrational Phase 3 trial enrolling 150 patients with relapsed peripheral T cell lymphoma, backed by FDA Fast Track and Orphan Drug designations. The clinical-stage biopharmaceutical company reported a net loss of $15.3 million for 2025 against an accumulated deficit of $412.3 million, and held $56.8 million in cash, equivalents, and marketable securities as of December 31, 2025.
Soquelitinib is also advancing in immune and inflammatory disease: a Phase 1 trial in moderate-to-severe atopic dermatitis showed a 72% mean reduction in EASI score at day 56 for patients on the drug versus 40% for placebo, supporting a Phase 2 trial of about 200 patients that began enrolling in March 2026. Corvus's second candidate, ciforadenant, an A2A receptor antagonist, is in a Kidney Cancer Research Consortium-run Phase 1b/2 trial combined with ipilimumab and nivolumab for metastatic renal cell carcinoma, having cleared an interim efficacy threshold in May 2024 with enrollment now complete. A third candidate, the anti-CD73 antibody mupadolimab, remains deprioritized behind the other two programs. Corvus relies entirely on third-party contract manufacturers, including a single manufacturer for mupadolimab drug substance, and does not operate its own manufacturing facilities.
Show full overview
With no products approved or generating revenue, Corvus's near-term value rests almost entirely on the PTCL Phase 3 readout for soquelitinib, since no FDA-approved therapies currently exist for relapsed PTCL and a negative or delayed result would remove the company's most advanced asset. A January 23, 2026 follow-on offering raised approximately $189.4 million in net proceeds, extending the company's cash runway into the second quarter of 2028 — spanning the expected Phase 3 readout window — while Angel Pharmaceuticals, a China-based joint venture holding greater-China rights to all three clinical candidates, develops the programs regionally without contributing capital Corvus can otherwise access.
See also: Healthcare · Biotechnology
From Corvus Pharmaceuticals, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated 2026-07-06Recent Developments — Corvus Pharmaceuticals, Inc.
Latest news
- NEWS 10 Health Care Stocks With Whale Alerts In Today’s Session — benzinga Jul 1, 2026 neutral
- NEWS Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals — benzinga Jun 9, 2026 positive
- NEWS Corvus Pharma Q1 EPS $(0.15), Inline — benzinga May 7, 2026 neutral
- NEWS Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Gol — benzinga Apr 17, 2026 positive
- NEWS Crude Oil Tumbles 12%; State Street Posts Upbeat Earnings — benzinga Apr 17, 2026 neutral
Generated 2026-07-06T06:00:34Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinesoquelitinib10-K Item 1: 'Our lead product candidate, soquelitinib (formerly CPI-818), is designed to bind specifically to a protein'
- HIGHSuppliermupadolimab manufacturer10-K Item 1: 'on one manufacturer for mupadolimab drug substance and other third-party manufacturers to produce our other product candidates.'
Material Events(8-K, last 90d)
- 2026-04-23Item 5.02LOWOn April 22, 2026, the Board appointed Andrew C. Chan, M.D., Ph.D. as a Class II director effective April 23, 2026, a routine board expansion with standard non-employee director compensation.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·1 ceiling hit
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 5.4% daily ATR makes tight stops impractical. Position-size conservatively.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $15.30: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 6.0:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 24%; Elevated put/call ratio: 6.09; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $14.16. Score 5.3/10, moderate confidence.
Take-profit target: $29.00 (+90.4% upside). Prior stop was $14.16. Stop-loss: $14.16.
Concentration risk — Pipeline: soquelitinib; Concentration risk — Supplier: mupadolimab manufacturer; Quality below floor (1.5 < 4.0).
Corvus Pharmaceuticals, Inc. trades at a P/E of N/A (forward -16.1). TrendMatrix value score: 9.0/10. Verdict: Sell.
13 analysts cover CRVS with a consensus score of 4.2/5. Average price target: $33.
What does Corvus Pharmaceuticals, Inc. do?Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company whose lead candidate, soquelitinib, an oral ITK...
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company whose lead candidate, soquelitinib, an oral ITK inhibitor, is in a registrational Phase 3 trial for relapsed peripheral T cell lymphoma and a Phase 2 trial for atopic dermatitis. The company has not generated product revenue, reported a $15.3 million net loss and $412.3 million accumulated deficit for 2025, and held $56.8 million in cash and marketable securities at year-end before a $189.4 million follow-on offering in January 2026.